標題: A real world cost effectiveness analysis of interferon-based therapy for HCV naive super-responders
作者: Tsai, Pei-Chien
Liu, Ta-Wei
Huang, Chung-Feng
Yeh, Ming-Lun
Dai, Chia-Yen
Chuang, Wan-Long
Huang, Jee-Fu
Yu, Ming-Lung
生物科技學院
College of Biological Science and Technology
關鍵字: Chronic hepatitis C;Cost-effectiveness analysis;Naive;Pegylated interferon;Response-guided therapy
公開日期: 1-八月-2018
摘要: Background: A direct-acting antiviral (DAA) era in hepatitis C virus (HCV) treatment is fast approaching; unfortunately, the availability and affordability of DAAs in Asia Pacific areas vary, making it difficult to develop universal HCV practice guidelines appropriate for the all Asian populations. This study aimed to evaluate the real-world cost-effectiveness of IFN-based therapy according to the current strategies with PegIFN/RBV for "easy-to-treat" to provide a reference for application of future DAA development for IFN-eligible, treatment nave HCV patients. Methods: A total of 1032 chronic hepatitis C treatment-naive patients who corresponded to response-guided therapy (RGT) guidelines of PegIFN/RBV regimens were linked to the entire population of expenditures and order in the National Health Insurance Research Database of Taiwan. The average total cost per SVR achieved was calculated as the summation of the total cost for all treated patients/number of SVR cases. Results: Current RGT suggested 24 weeks of PegIFN/RBV for GI naive patients with baseline LVL and RVR at treatment week 4 achieved an average treatment cost per SVR of $5090 +/- 2400. This was of superior cost-effectiveness compared with those other subgroups of GI patients. In terms of G2 patients, according to current RGT of 16 weeks of treatment duration, PegIFN/RBV treatment with RVR achieved was of a very competitive cost per SVR ($3237 +/- 488). Conclusion: For a nave patient in the new DAA era, the PegIFN/RBV treatment might be conserved for those with all favorable risk parameters, considering the treatment duration and cost per SVR, in the resource-constrained countries. Copyright (C) 2018, the Chinese Medical Association. Published by Elsevier Taiwan LLC.
URI: http://dx.doi.org/10.1016/j.jcma.2017.05.015
http://hdl.handle.net/11536/147906
ISSN: 1726-4901
DOI: 10.1016/j.jcma.2017.05.015
期刊: JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
Volume: 81
起始頁: 670
結束頁: 675
顯示於類別:期刊論文